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The purpose of this study is to determine whether differences in protein expression exist between 
patients with inflammatory bowel disease (IBD), both Crohn’s Disease (CD) and Ulcerative 
Colitis (UC), irritable bowel syndrome (IBS), and healthy controls (HC). A total of fourteen 
colonic biopsies (n=14, 8-IBD, 4-IBS, 2-HC) underwent nucleus counts using the nCounter 
software of the Nanostring GeoMx Digital Spatial Profiler (NanoString Technologies, Inc., 
Seattle, Washington, USA). Three regions of interest were stained according to tryptase, crypt, 
and connective tissue and visualization markers were attached to fluoresce thirty inflammatory 
and oncological proteins of interest. After nucleus counts for proteins of interest were plotted in 
Tableau (2020.4.0), overexpression of AKT, beta-catenin, histone H3, CD44, S6, STAT3 were 
apparent for both IBD and IBS. The overexpressed proteins endorse mostly positive correlational 
relationships according to the bivariate correlation conducted in IBM SPSS Statistics (Version 
27) predictive analysis software. Establishing validated levels of elevated protein expression 
offers the clinical opportunity to devise diagnostic biomarkers. Solidifying knowledge of the 
relationships between the inflammatory proteins provides potential understanding into the 
similarities of IBS and IBD.   
 Keywords: IBD, Crohn’s Disease, Ulcerative Colitis, IBS, protein expression, 
inflammation, oncologic activity, biomarkers  
Background   
The incidence of inflammatory bowel disease (IBD) has been increasing internationally 
with a total of 5.2 million people in North America and Europe currently diagnosed 
(Ananthakrishnan et al., 2020).  IBD is an autoimmune illness encompassing Crohn’s Disease 
(CD) and Ulcerative Colitis (UC) which can vary from mild to severe based on symptoms and 
colon integrity. UC is generally superficial, continuous inflammation occurring in the submucosa 
of the large intestine whereas CD is transmural inflammation mixed between healthy intestines 
that can manifest anywhere in the gastrointestinal tract. The etiology is unknown but a genetic 
link has been observed and environmental factors such as smoking, microbiome diversity, oral 
contraceptives, antibiotics, nonsteroidal anti-inflammatory drugs (NSAIDS), and 
appendectomies have been studied with some correlational evidence (Ko et al., 2014).  
More importantly, IBD can induce tissue damage and subsequently, through chronic 
inflammation, colon cancer (Beaugerie & Itzkowitz, 2015; Nebbia et al., 2020; Stidham & 
Higgins, 2018). Some studies have shown those with IBD are twice as likely to get colorectal 
carcinoma compared to healthy individuals (Beaugerie & Itzkowitz, 2015). According to the 
American Gastroenterology Association, endoscopy surveillance is recommended every 1-2 
years for adults with IBD (Shah & Itzkowitz, 2020). Noninvasive tools such as the Crohn’s 
Disease Activity Index, Harvey-Bradshaw Index, and Partial Mayo Scoring Index score the 
severity of the disease based on symptomology subjectively reported by patients. However, these 
methods of scoring do not provide an accurate picture of what is occurring endoscopically or 
histologically making them less than ideal for tracking inflammation (Lewis et al., 2020). 
Additionally, serum biomarkers like C-reactive protein (CRP) or erythrocyte sedimentation rate 
(ESR) lack sensitivity and do not correlate with inflammation of the bowel wall (Porter et al., 
2020). Fecal calprotectin is able to identify colonic inflammation but does not show small 
intestine inflammation (Porter et al., 2020). This leaves colonoscopies or other forms of 
endoscopy to be the gold standard in diagnosing and monitoring IBD. It is important to note that 
for some patients, it is contraindicated to perform colonoscopies. Studies have shown patients 
with IBD are at an 8-fold increased risk of colonoscopy-induced adverse events such as 
perforations (Mukewar et al., 2014). Colonoscopies are costly, and demanding procedures 
requiring a clear-liquid diet 24 hours before the procedure and a liquid prep to cleanse the colon. 
As a result, many patients with IBD are not compliant with surveillance colonoscopies despite 
being a high-risk population for developing colon cancer (Davis et al., 2013).  Therefore, it is 
challenging for clinicians to determine when patients are in remission or in a flare noninvasively. 
More biomarkers are needed to adequately assess disease progression as well as response to 
pharmaceutical interventions. Inflammatory marker specificity between IBS and IBD is also 
needed to avoid unnecessary colonoscopies or misdiagnoses.  
IBS is diagnosed based on fulfilling two of the categories on the Rome Criteria. Patients 
with abdominal pain once or more per day or week are screened for increased or decreased pain 
with defecation, changes in stool frequency, and changes in stool appearance. IBS-C is a 
decrease in the number of bowel movements with more solid stools as designated by the Bristol 
stool chart. IBS-D refers to an increase in frequency of bowel movements with more loose stools 
as designated by six or seven on the Bristol stool chart. Evidently, the symptoms of IBS and IBD 
can be similar. IBS is considered the most prevalent functional gastrointestinal disorder yet there 
is no biomarker or gold standard of diagnosing IBS (Lacy & Patel, 2017). One study showed 
10% of IBD patients were misdiagnosed with IBS for several years (Card et al., 2014). 
Treatment for IBS does not address the inflammatory process thus a misdiagnosis prevents 
patients from getting adequate care. More biomarkers in the clinical setting would mean an 
increase in patient safety through a decrease in invasive procedures, a decrease in healthcare 
costs, and greater opportunity for accurate diagnoses.  
 
Introduction 
Quantitative protein expression has been a major prospect of cancer research and clinical 
biomarker development (McNamara et al., 2021; Mungenast et al., 2021; Kang et al., 2021). The 
Nanostring GeoMx DSP has allowed researchers to explore the tumor microenvironment and 
generate information regarding cancer development. Previous studies conducted by Galon et al. 
(2011) and Bindea et al. (2013), looked at the  ratio of the markers CD3 and CD45RO, CD3 and 
CD8, or CD8 and CD45RO as colorectal cancer diagnostic measures. The protein ratios can be 
further evaluated using GeoMx to confirm significance in cancer progression and thus develop 
more specific cancer treatments (Mungenast et al., 2021). The proteins discussed in this paper 
include AKT, CD44, STAT3, beta-catenin, histone H3, and S6.  AKT, being a protein kinase, 
phosphorylates other proteins that can either promote or inhibit certain cell activity. AKT 
regulates metabolism, proliferation, cell survival and growth, angiogenesis and the uptake of 
glucose into the cell. AKT is a central protein in signal  transduction pathways and has been 
involved in susceptibility to colon cancers (Bateman et al., 2020). CD44 is a cell-receptor protein 
involved in cell adhesion and migration. CD44 plays a pivotal role in the signal transduction 
pathway resulting in activation of T-lymphocytes and inflammation (Bateman et al., 2020). 
Elevated levels of CD44 have been associated with certain cancers. STAT3 or signal transducer 
and activator of transcription 3 mediates cellular response to interleukins and growth factors. It 
also regulates the inflammatory response by regulating differentiation of CD4+ T-cells into T-
Helper cells. High levels of STAT3 are associated with certain cancers. Beta-Catenin regulates 
cell adhesion as a downstream signal of canonical Wnt pathway. Increased activity of beta-
catenin is linked to several cancers, including colorectal (Bateman et al., 2020). Histone H3 is a 
transcription regulator involved in DNA repair and post-translational modifications. S6 is part of 
the small 40S ribosomal subunit which is responsible for cell growth and proliferation (Bateman 
et al., 2020). Understanding the cellular pathways of the proteins involved in the inflammatory 
and oncogenic process continues to be a focal point of targeted therapy for IBD and cancers.  
Methods  
Data published by Henderson et al. (2020) was used to compare protein expression 
among IBD, IBS and healthy control. IRB approval was not required since data is public and 
contains no information that could potentially identify participants. Formalin-fixed paraffin 
embedded (FFPE) colonic samples were masked according to three regions of interest, one being 
tryptase, two is crypt and the third is connective tissue. The total sample size is fourteen, four 
colonic biopsies were taken from patients with IBS, eight from patients with IBD, and two were 
from healthy patients. All patients experienced moderate abdominal pain and were untreated 
prior to collection of biopsies. Nucleus counts were performed using Nanostring GeoMx Digital 
Spatial Profiler (DSP). GeoMx is done by attaching photocleavable oligonucleotides to the 30 
inflammatory/oncological proteins’ antibodies and manually staining for the regions of interest 
as seen in figure 1. One protein was Rabbit IgG which was used as an internal negative control 
because there should be no expression of rabbit antibodies in human samples. Once regions of 
interest are stained/fluorescent, the ultraviolet light detaches the oligonucleotides which can then 
be placed onto a microtiter plate for the GeoMx DSP software to count. For this analysis the 
nuclei counts for the three regions of interest were utilized for comparison. GeoMx is a novel 
instrument that allows for the quantification of proteins without damaging the sample or 
requiring amplification. The nucleus counts were then separated according to region of interest 
and a bivariate correlation between proteins was conducted. Data were then visualized using 





Note. Process of collecting nucleus counts indicated in the protein pathway in the image. 













The masked FFPE colonic samples for each patient are indicated in Figures 2 through 15. 
The nCounter software can quantify protein expression through nucleus counts. Graphs were 
created to visualize the data in Figures 16 through 18. The proteins with higher nucleus counts 
for each region were included in bivariate correlation Tables 1 through 3. 
The results of the visualization conducted on Tableau indicate increased protein 
expression for CD44, beta-catenin, STAT3, S6 and histone H3 as seen in Figure 16. In Figure 17 
and 18, AKT, beta-catenin, histone H3, STAT3, and S6 had marked increases compared to 
healthy control samples.  Expression of VISTA was noted only in connective tissue and crypt for 
patients with IBD.  
The bivariate correlation run through SPSS revealed significant correlation between most 
of the proteins. However, when considered with the data visualization, the bivariate correlation 
served as a confirmation of positive association between the proteins of interest. However, for 
STAT3, positive association was not significant. STAT3 also did not have any relationship with 
beta-catenin and histone when run through the String database. Beta-catenin, has experimentally, 









FFPE Fluorescent IBS-5 Slides Masked with Visualization Markers with ROI Circled  
 
 
Note. A. The red tryptase visualization marker allows for distinguishing the tryptase rich 
environment for selection in the image directly below. B. The blue nuclei visualization marker 
highlights the crypt microenvironment for protein analysis in the region. C. PanCK green 
visualization marker displays the connective tissue environment for protein analysis.  
Figure 3 
FFPE Fluorescent IBS-10 Slides Masked with Visualization Markers with ROI Circled  
 
Note. A. Tryptase ROI-1, B. Crypt ROI-2, C. Connective ROI-3 
Figure 4 
FFPE Fluorescent IBS-4 Slides Masked with Visualization Markers with ROI Circled  
 
Note. A. Tryptase ROI-1, B. Crypt ROI-2, C. Connective ROI-3 
Figure 5  
FFPE Fluorescent IBS-1 Slides Masked with Visualization Markers with ROI Circled  
 
Note. A. Tryptase ROI-1, B. Crypt ROI-2, C. Connective ROI-3 
Figure 6 
FFPE Fluorescent IBD-6 Slides Masked with Visualization Markers with ROI Circled  
 
Note. A. Tryptase ROI-1, B. Crypt ROI-2, C. Connective ROI-3 
Figure 7 
FFPE Fluorescent IBD-19 Slides Masked with Visualization Markers with ROI Circled  
 
Note. A. Tryptase ROI-1, B. Crypt ROI-2, C. Connective ROI-3 
Figure 8 
FFPE Fluorescent IBD-18 Slides Masked with Visualization Markers with ROI Circled  
 
Note. A. Tryptase ROI-1, B. Crypt ROI-2, C. Connective ROI-3 
Figure 9 
FFPE Fluorescent IBD-7 Slides Masked with Visualization Markers with ROI Circled  
 
Note. A. Tryptase ROI-1, B. Crypt-ROI-2, C. Connective-ROI-3 
Figure 10 
FFPE Fluorescent IBD-3 Slides Masked with Visualization Markers with ROI Circled  
 
Note. A. Tryptase ROI-1, B. Crypt ROI-2, C. Connective ROI-3 
Figure 11 
FFPE Fluorescent IBD-15 Slides Masked with Visualization Markers with ROI Circled  
 
Note. A. Tryptase ROI-1, B. Crypt ROI-2, C. Connective ROI-3 
Figure 12 
FFPE Fluorescent IBD-12 Slides Masked with Visualization Markers with ROI Circled  
 
Note. A. Tryptase ROI-1, B. Crypt ROI-2, C. Connective ROI-3 
Figure 13 
FFPE Fluorescent IBD-13 Slides Masked with Visualization Markers with ROI Circled  
 
Note. A. Tryptase ROI-1, B. Crypt ROI-2, C. Connective ROI-3 
Figure 14 
FFPE Fluorescent Healthy Control-1 Slides Masked with Visualization Markers with ROI 
Circled  
 
Note. A. Tryptase ROI-1, B. Crypt ROI-2, C. Connective ROI-3 
Figure 15 
FFPE Fluorescent Healthy Control-2 Slides Masked with Visualization Markers with ROI 
Circled  
 



















Nucleus Count for Inflammatory and Oncologic Proteins in Tryptase Masked Colonic Samples  
 
Note. Protein nucleus count data for tryptase stained colonic biopsies were plotted in Tableau 
software. The x-axis is scaled independently for each patient with ranges of nucleus counts from 












Nucleus Count for Inflammatory and Oncologic Proteins in Crypt Masked Colonic Samples 
 
Note. Protein nucleus count data for crypt stained colonic biopsies are visualized. The x-axis is 
scaled independently for each patient with ranges of nucleus counts from 0-40. Increased 










Figure 18  




Note. Protein nucleus count data for connective tissue stained colonic biopsies were inputted into 
Tableau for visualization. The x-axis is scaled independently for each patient with ranges of 
nucleus counts from 0-40. Increased expression of AKT, beta-catenin, Histone H3, S6, and 









Tryptase Stained Colonic Samples’ Bivariate Correlation Between Proteins  
 
Measure   1  2  3  4  5 
 
1. Beta-Catenin --  0.91**  0.91**  0.93**  0.65** 
2. CD44  0.91**  --  0.80**  0.75**  0.58 
3. Histone H3  0.91**  0.80**  --  0.93**  0.77**  
4. S6   0.88**  0.75**  0.93**  --  0.81** 
5. STAT3  0.65**  0.58  0.76**  0.81**  -- 
 
Note. The 31 proteins (n=31) were inputted into the bivariate correlation through IBM SPSS. 
The proteins with elevated expressions noted in Figure 16 from Tableau are listed in the 
correlational table. Significant correlation is observed between all the proteins except STAT3 











Crypt Stained Colonic Samples’ Bivariate Correlation Between Proteins  
 
Measure   1   2   3  4  5 
 
1. AKT  --  0.815** 0.93**  0.921** 0.604  
2. Beta-Catenin 0.815** --  0.854** 0.872** 0.596  
3. Histone H3  0.93**  0.854** --  0.923** 0.669** 
4. S6   0.921** 0.872** 0.923** --  0.712** 
5. STAT3  0.604  0.596  0.669** 0.712** -- 
 
Note. The 31 proteins (n=31) were inputted into the bivariate correlation through SPSS. The 
proteins with elevated expressions noted in Figure 17 from Tableau are listed in the correlational 
table. STAT3 fails to have significant correlation between AKT and Beta-Catenin with p values 











 Connective Tissue Masked Colonic Samples’ Bivariate Correlation Between Proteins  
 
Measure   1   2  3  4  5 
 
1. AKT  --  0.624  0.853** 0.747** 0.174 
2. Beta-Catenin 0.624  --  0.645*  0.562  0.078 
3. Histone H3  0.853** 0.645*  --  0.876** 0.228 
4. S6   0.747** 0.562  0.876** --  0.325 
5. STAT3  0.174  0.078  0.228  0.325  -- 
 
Note. The 31 proteins (n=31) were inputted into the bivariate correlation through SPSS. The 
proteins with elevated expressions noted in Figure 18 from Tableau are listed in the correlational 
table. A lack of correlation between STAT3 and AKT (p=0.589), beta-catenin (p=0.809), 
Histone H3 (p=0.476), and S6 (p=0.303) is evident through elevated p values. Beta-catenin 










Visualization of Inflammatory and Oncological Protein Relationships  
 
Note.  A. Image includes 23 of the 30 inflammatory or oncogenic proteins run through the String 
database. B. The image on the right shows only the proteins that were overexpressed within the 
three regions of interest.  For both images, the pink line shows the experimentally confirmed 
interactions, the black line indicates co-expression, and the blue line represents database curated 
interactions. The green line has no significance besides connecting the proteins. AKT and beta-
catenin (CTNNB1) have the most established relationships.  
 
Discussion  
The proteins found to be highly expressed across the regions of interest are generally 
responsible for promoting cellular proliferation. Of note is the expression of VISTA seen only in 
those with IBD for crypt and connective tissue masked samples thus being an ideal candidate for 
future research. VISTA is an immune checkpoint protein that suppresses T-cell activation and 
subsequent cytokines (Lines et al., 2014). VISTA could be a potential mechanism to counteract 
excessive inflammation and thus was not seen with IBS. Due to the fact that it is only expressed 
in certain microenvironments of patients with IBD, it could be used as a biomarker for diagnosis. 
GeoMx allows for quantification of proteins in specific colonic regions thus improving 
biomarker and cancer research. The efficacy of specific treatments through targeted pathway 
inhibition can be explored more easily. It is expected that inflammatory proteins would be 
elevated in colonic samples of patients with IBD. However, the patients with IBS also exhibited 
increased expression of the same proteins suggesting more research is needed to understand the 
pathogenesis of IBS. Moreover, the oncogenic activity of beta-catenin, STAT3, and CD44 
provides potential noninvasive colon cancer surveillance. As more research is conducted, these 
protein markers can be used to monitor disease progression.  Understanding expression of these 
proteins can also individualize pharmacological therapies for patients with IBD and determine 
efficacy of response to treatment. For instance, tofacitinib (Xeljanz), a JAK/STAT inhibitor, has 
evidence of efficacy in patients with ulcerative colitis when anti-tumor necrosis factor blockers 
are ineffective. If a patient has elevated STAT3, which was seen in the colonic samples of 
patients with IBD, it can be predicted that tofacitinib’s inhibitory effect would lead to a reduction 
in inflammation for these patients. Ultimately, knowing which inflammatory proteins are highly 
expressed, would indicate to a clinician which inflammatory pathway(s) is/are specifically 
activated and therefore prescribe treatment to target it.    
Limitations 
 This research included a small sample size. Only 14 colonic samples were analyzed thus 
preventing generalizations and adequate statistical analysis. All proteins discussed in this study 
are known inflammatory or oncological proteins therefore a bias is present. The data were also 
missing a positive internal control so expression seen could not be compared to a known colonic 
protein. Finally, GeoMx DSP is a novel instrument and therefore is not validated.  
Conclusion 
IBD is increasing internationally with no valid noninvasive methods to diagnose and 
monitor the disease. The purpose of this research was to compare protein expression between 
IBD, IBS and healthy control using GeoMx DSP to quantify nucleus counts. By researching 
protein expression, insight into pathophysiology can be established and thus improve diagnostics 
and treatment. The results revealed beta-catenin, CD44, histone H3, S6, STAT3 were 
overexpressed in ROI-1 with a strong positive correlation seen with the exception of CD44 with 
STAT3. For ROI-2 AKT, beta-catenin, histone H3, S6, STAT3 were overexpressed with a 
positive correlation except for STAT3 with beta-catenin and AKT. For ROI-3, AKT, beta-
catenin, histone H3, S6, STAT3 were overexpressed but STAT3 had no correlation with any of 
the other proteins. In general, these proteins are involved in cellular growth and proliferation 
making them practical to observe in the future in relation to IBD. Individualizing therapies based 
on the guidance of biomarkers would increase quality of treatment and decrease the trial and 
error of bottom-up treatment. More biomarkers are needed to address the deficiency of 
diagnostic options, the steep cost, and dangers of endoscopy.  
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